ArticleScience advances2021
Human tumor microenvironment chip evaluates the consequences of platelet extravasation and combinatorial antitumor-antiplatelet therapy in ovarian cancer.
Article in Science advances, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 82 citations in OpenAlex.
- Engineering Multiscale Vasculature: Biological Principles, Design Constraints, and Advanced Biofabrication Strategies for Functional Vascular Networks.Biomimetics (Basel, Switzerland) · 2026Review
- Tumor-platelet cross talk in cancer: mechanisms, thrombotic risk, and translational opportunities.Blood advances · 2026Review
- Platelets as localized conduits of TGF-β1 in the tumor microenvironment: implications for cancer progression and therapy.Human cell · 2026Review
- Nanoparticle based siRNA therapeutics for ovarian cancer overcoming drug resistance and future directions.Discover nano · 2026Review
- Models of high-grade serous carcinoma of tubo-ovarian origin.Oncology reviews · 2026Review
- Construction and validation of a preoperative malignancy risk prediction model for ovarian-adnexal masses based on clinical and ultrasonographic features.Frontiers in medicine · 2026Article
- Platelet‑circulating tumor cell crosstalk: A pivotal target in cancer diagnosis and therapy (Review).Oncology reports · 2026Review
- Network Controllability Reveals Key Mitigation Points for Tumor-Promoting Signaling in Tumor-Educated Platelets.International journal of molecular sciences · 2025Article
- Tumour-on-Chip Models for the Study of Ovarian Cancer: Current Challenges and Future Prospects.Cancers · 2025Review
- Vascularized Tumor-on-a-Chip Model as a Platform for Studying Tumor-Microenvironment-Drug Interaction.Macromolecular bioscience · 2025Review
- Unveiling the "Dark Matter" of platelet involvement in tumor microenvironment.Journal of pharmaceutical analysis · 2025Review
- 3D Multi-Tissue microphysiological system for Anti-Cancer and cardiotoxicity drug screening with automated image analysis.Discover applied sciences · 2025Article
- Micro-hydrogel molding-assisted fabrication of a PDMS-based microfluidic concentration-gradient generator for dynamic anticancer drug testing.RSC advances · 2025Article
- Modeling reproductive and pregnancy-associated tissues using organ-on-chip platforms: challenges, limitations, and the high throughput data frontier.Frontiers in bioengineering and biotechnology · 2025Review
- Hydrogel Design to Understand and Guide 3D Cell Migration.Regenerative engineering and translational medicine · 2025Review
- Microfluidics as a promising technology for personalized medicine.BioImpacts : BI · 2025Review
- From mechanisms to precision medicine: the role of organoids in studying the gut microbiota-tumor microenvironment axis.Frontiers in microbiology · 2025Review
- Targeted Cancer Therapy-on-A-Chip.Advanced healthcare materials · 2024Review
- Elevated Platelet Aggregation in Patients with Ovarian Cancer: More than Just Increased Platelet Count.Cancers · 2024Article
- Vascularized tumor models for the evaluation of drug delivery systems: a paradigm shift.Drug delivery and translational research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
Platelets extravasate from the circulation into tumor microenvironment, enable metastasis, and confer resistance to chemotherapy in several cancers. Therefore, arresting tumor-platelet cross-talk with effective and atoxic antiplatelet agents in combination with anticancer drugs may serve as an effective cancer treatment strategy. To test this concept, we create an ovarian tumor microenvironment chip (OTME-Chip) that consists of a platelet-perfused tumor microenvironment and which recapitulates platelet extravasation and its consequences. By including gene-edited tumors and RNA sequencing, this organ-on-chip revealed that platelets and tumors interact through glycoprotein VI (GPVI) and tumor galectin-3 under shear. Last, as proof of principle of a clinical trial, we showed that a GPVI inhibitor, Revacept, impairs metastatic potential and improves chemotherapy. Since GPVI is an antithrombotic target that does not impair hemostasis, it represents a safe cancer therapeutic. We propose that OTME-Chip could be deployed to study other vascular and hematological targets in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.